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The aim of this study was to investigate whether the VKORC1∗3 (rs7294/9041 G>A), VKORC1∗4 (rs17708472/6009 C>T),
and CYP4F2 (rs2108622/1347 C>T) polymorphisms were associated with elevated warfarin maintenance dose requirements in
patients with myocardial infarction (n = 105) from the Warfarin Aspirin Reinfarction Study (WARIS-II). We found signiﬁcant
associations between elevated warfarin dose requirements and VKORC1∗3 and VKORC1∗4 polymorphisms (P = .001 and P =
.004, resp.), whereas CYP4F2 (1347 C>T) showed a weak association on higher warfarin dose requirements (P = .09). However,
analysing these variant alleles in a regression analysis together with our previously reported data on VKORC1∗2, CYP2C9∗2a n d
CYP2C9∗3 polymorphisms, gave no signiﬁcant associations for neither VKORC1∗3, VKORC1∗4 nor CYP4F2 (1347 C>T). In
conclusion, in patients with myocardial infarction, the individual contribution to warfarin dose requirements from VKORC1∗3,
VKORC1∗4, and CYP4F2 (1347 C>T) polymorphisms was negligible. Our results indicate that pharmacogenetic testing for
VKORC1∗2, CYP2C9∗2 and CYP2C9∗3 is more informative regarding warfarin dose requirements than testing for VKORC1∗3,
VKORC1∗4, and CYP4F2 (1347 C>T) polymorphisms.
1.Introduction
Warfarin has an established role in secondary prevention
of atherothrombotic disease, reducing new thromboembolic
events [1]. However, warfarin dosage is a challenge to
clinicians because of its narrow therapeutic range and
patient variability in obtained INR levels. An important
issue is to improve individual warfarin dose prediction,
especially in the initial phase of treatment, in order
to avoid thrombosis and treatment-induced bleeding. An
increasing number of genetic variations aﬀecting warfarin
pharmacokinetics and/or pharmacodynamics have recently
been reported to have major impact on dosage require-
ments, that is, polymorphisms in the CYP2C9, VKORC1,
and CYP4F2 genes [2–7]. In Caucasians, the VKORC1
gene is represented by three main haplotypes: VKORC1∗2
(rs9934438/6484 C>T), VKORC1∗3 (rs7294/9041 G>A),
and VKORC1∗4 (rs17708472/6009 C>T) [8]. Previously
we have found VKORC1∗2 to account for 24.5%, and
the combination of CYP2C9∗2 and CYP2C9∗3 (rs1799853
and rs1057910) to account for 7.2% of the warfarin
maintenance dose variation in patients from the War-
farin Aspirin Reinfarction Study (WARIS-II) [9]. In the
present investigation, we aimed to study whether the high-
dose polymorphisms VKORC1∗3, VKORC1∗4, and CYP4F2
(rs2108622/1347 C>T) were associated with elevation in
warfarin maintenance dose requirements in the same patient
group.2 Journal of Biomedicine and Biotechnology
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Figure 1: Box plot of mean weekly warfarin maintenance dose for
combinationsofdiﬀerentVKORC1haplotypes.Theboxesrepresent
the values from the 25th to 75th percentile. The middle lines
represent the median. The vertical lines extend from the minimum
values to the maximam values, excluding outliers and extreme
values marked with open circles and asterisk, respectively. The
P-value indicates the statistical signiﬁcance of the diﬀerence in
mean weekly warfarin dose between patients with or without the
VKORC1∗2 haplotype (Mann-Whitney test).
2. Methods
2.1. Patients. The patients in this study were a subgroup of
the WARIS-II trial who had been assigned to three diﬀerent
antithrombotic regimens after acute myocardial infarction
[10]. All patients provided written informed consent before
participation in the study. The patients were randomly
assigned to treatment with either a daily dose of 160mg
aspirin, warfarin (target INR 2.8–4.2), or 75mg of aspirin
combined with warfarin (target INR 2.0–2.5) and followed
for 4 years. Blood samples for genotyping were available for
212 patients from Oslo University Hospital, Ullev˚ al. Of the
140 patients on warfarin treatment, from both treatment
groups combined, 105 patients were informative for weekly
warfarin maintenance dose and used for genetic association
analyses (Warfarin total group, Table 1).
2.2. Genotyping. Genomic DNA was isolated from 200µL
EDTA whole blood as described earlier [9]. The VKORC1∗3
(rs7294/9041 G>A) polymorphism was PCR ampliﬁed on
a LightCycler (Roche.com) real-time instrument under stan-
dard conditions essentially as reported [9] with an annealing
temperature of 60◦C. Forward and reverse primers were 5’-
GAGCCTTGCCTAAGGG and 5’-TGGAAAGAGCTTTGG-
AGAC, respectively, whereas the LC Red640-labelled sensor
probe and the ﬂuorescence-labelled anchor probe were 5’-
TGTGCGGGTATGGCAGGA and 5’-CGTGTGGCACAT-
TTGGTCCATTGT, respectively. Genotypes were deter-
mined by melting point analyses. CYP4F2 (rs2108622/1347
C>T) and VKORC1∗4 (rs17708472) were genotyped by
TaqMan assays on ABI 7900 HT Fast PCR system (Applied
Biosystems, CA, USA). Primers and probes for the CYP4F2
(1347 C>T) assay were commercially available at ABI
(cat no C 16179493 40), whereas primers and probes for
VKORC1∗4 (rs17708472/6009 C>T) were custom made
by ABI (forward primer: 5’GCCCGGCCCTTAAGTAATT-
CTT, reverse primer: 5’TCCCAGTCTCTGATGCAAAACC,
wild-type probe: VIC-TGAACCGTTATACTAGCCTTG,
mutant probe: Fam-CCGTTATACCAGCCTTG). Geno-
typing of VKORC1∗2 (rs9934438/6484 C>T), CYP2C9∗2
(rs1799853), and CYP2C9∗3 (rs1057910) was done previ-
ously [9].
2.3. Statistical Analysis. Statistical analysis was performed
using SPSS 16.0 statistic software (SPSS Inc., Chicago, IL,
USA) and PLINK (http://pngu.mgh.harvard.edu/purcell/pl-
ink/). SNPs were tested for deviation from Hardy-Weinberg
equilibrium using exact tests [11]. The Mann-Whitney U-
testwasusedtotestthediﬀerenceinwarfarindosagebetween
two groups. Multivariate regression analyses were performed
to evaluate the individual impact of VKORC1∗3, ∗4, and
CYP4F2 (1347 C>T) polymorphisms on mean warfarin
maintenance dose, after adjustment for the covariates age
and treatment group. The signiﬁcance level of P ≤ .05 was
set for entry into the ﬁnal model.
3. Results
Genotype distributions of the VKORC1∗2, VKORC1∗3,
VKORC1∗4, and CYP4F2 (1347 C>T) polymorphisms in
212 patients from the Oslo subset of the WARIS-II trial
are summarized in Table 1. None of the Single Nucleotide
Polymorphisms (SNPs) deviated from the Hardy-Weinberg
equilibrium. Combined with our previous WARIS-II data
[9], three polymorphisms in the VKORC1 gene have been
analysed representing three distinct haplotypes: VKORC1∗2,
VKORC1∗3, and VKORC1∗4. Lack of any of these hap-
lotypes was considered as VKORC1∗1. The VKORC1∗1
haplotype was found in one patient only (Table 1).
Boxplot of mean weekly warfarin dose for combina-
tions of diﬀerent VKORC1 haplotypes is shown (Figure 1).
Patients homozygous for the VKORC1∗2 haplotype had
signiﬁcantly lower mean warfarin maintenance dose com-
pared to patients homozygous for either VKORC1∗3o r
∗4h a p l o t y p e s( P<. 001 and P = .003, resp., Mann-
Whitney), whereas there was no signiﬁcant diﬀerence in
warfarin dosage between homozygotes of VKORC1∗3a n d
∗4( P = .80, Mann-Whitney). Heterozygotes with combi-
nations of VKORC1∗2 and VKORC1∗3o r∗4 haplotypes
had signiﬁcantly lowered maintenance dose compared to
heterozygotes of VKORC1∗3a n d∗4( P = .002 and P = .023,
resp., Mann-Whitney). There was a slight increase in mean
weekly warfarin dose in patients who were heterozygous
(CT), but not for patients who were homozygous (TT) for
the CYP4F2 (1347 C>T) T allele compared to patients with
the normal CC-genotype (P = .14 and P = .51, resp.,
Mann-Whitney), indicating a lack of trend between the three
CYP4F2 genotypes (Figure 2). In three separate multivariateJournal of Biomedicine and Biotechnology 3
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Figure 2: Box plot of mean weekly warfarin maintenance dose for
combinations of diﬀerent CYP4F2 genotypes. The boxes represent
the values from the 25th to 75th percentile. The middle lines
represent the median. The vertical lines extend from the minimum
values to the maximum values.
regression analyses, VKORC1∗3 and VKORC1∗4 were asso-
ciated with higher dose requirements when adjusted for age
and treatment group only (P = .001 and P = .004, resp.),
while CYP4F2 (1347 C>T) showed a weak association on
higher warfarin dose requirement (P = .09). However, a
stepwise multivariate regression analysis of VKORC1∗3, ∗4,
and CYP4F2 (1347 C>T) together with our earlier reported
data on VKORC1∗2, CYP2C9∗2, and CYP2C9∗3, age and
treatment group gave no signiﬁcant associations for neither
VKORC1∗3, ∗4 nor CYP4F2 (1347 C>T).
4. Discussion
In our earlier study of 212 patients with myocardial
infarction (the WARIS-II Study), up to 32% of the variability
in warfarin dose requirements could be explained by the
VKORC1∗2, CYP2C9∗2, and CYP2C9∗3p o l y m o r p h i s m s
[9]. This is in accordance with results by Wadelius et al.
[6], where 201 Swedish patients with mixed indications
(mainly atrial ﬁbrillation and heart valve prosthesis) were
studied. Whereas all these three SNPs contributed to reduced
warfarin dosage requirements, the VKORC1∗3a n d∗4
haplotypes and recently the CYP4F2 (rs2108622/1347
C>T)-polymorphism have been associated with increased
dose requirement [2–6]. Carriers of any of these six genetic
variants may be at increased risk of being outside the narrow
therapeutic range for INR, especially during the initial phase
of the anticoagulation treatment. The combined eﬀect of
diﬀerent genetic variants upon warfarin dose requirement
may therefore be diﬃcult to foresee and needed to be
clariﬁed by further studies.
The frequencies of the three VKORC1 haplotypes
(∗2, ∗3, and ∗4) in this study were in concordance with
previous reports [8, 12–14]. In line with Osman et al. [13]
and Spreaﬁco et al. [14], we found that all carriers of the
VKORC1∗2 haplotype needed lower doses of warfarin
compared to VKORC1∗3a n d∗4 carriers, irrespective
of homozygosity or heterozygosity of the ∗2a l l e l e .I n
separate multivariate regression analysis, VKORC1∗3a n d
VKORC1∗4 were associated with higher dose requirements,
however, inclusion of both VKORC1∗3a n d∗4 into our
previously described regression model [9], did not explain
more of the variability in warfarin dose requirements,
possibly because the VKORC1 activities associated with
VKORC1∗3 and VKORC1∗4 were similar. Since the
contribution of diﬀerentiating between ∗3a n d∗4( h i g h
dose variants) to warfarin dosage was negligible compared
to the considerable contribution of ∗2 (low dose variant),
genotyping for VKORC1∗2 instead of VKORC1∗2, ∗3, and
∗4m a yb es u ﬃcient for routine purposes in Caucasians.
The genotype frequencies of the CYP4F2 (1347 C>T)
polymorphism in our study were similar to results from
others [3, 15]. This CYP4F2 variant, ﬁrst discovered by
Caldwell and coauthors [3], has been found to explain from
1.5%–7% of warfarin dosing variability [3, 15–17]. In our
studyof105patientswehad80%powertodetectsigniﬁcance
for CYP4F2 explaining 7% of the dose variance and 24%
power to detect signiﬁcance explaining a modest dosing
variability of 1.5%. The lack of association between the
CYP4F2 (1347 C>T) polymorphism and warfarin dosage in
this study indicates that the impact of this polymorphism on
warfarin dosage is likely to be small in Caucasians. However,
four of the seven patients who were homozygous for the
CYP4F2 TT-genotype were carriers of either VKORC1∗2o r
CYP2C9∗3( 2w e r eh o m o z y g o u sf o rV K O R C 1 ∗2a n d2w e r e
heterozygous for both VKORC1∗2 and CYP2C9∗3) which
may have confounded the CYP4F2 eﬀect.
Our ﬁndings based on myocardial infarction patients
conﬁrm that among the hitherto known genetic vari-
ants suspected to inﬂuence warfarin maintenance dosage,
VKORC1∗2, VKORC1∗3, and VKORC1∗4a r eo fm a j o r
importance in addition to CYP2C9 variants, whereas the
CYP4F2 (1347 C>T) polymorphism in Caucasians is likely
tobeofrelativelylittleimportance.Sincethelowdosevariant
VKORC1∗2 in particular, as well as the CYP2C9∗2a n d
CYP2C9∗3 variants explain up to 32% of the variability,
thesevariantalleleswouldprobablybesuﬃcientcomprehen-
sive genetic markers in Caucasians for individual warfarin
dose prediction in clinical routine. In order to make a more
complete survey of the genetic background for enzymes
aﬀecting individual warfarin pharmacokinetics and/or phar-
macodynamics, a full genotyping of the six current SNPs
is required. Populations with higher carrier frequency of
the VKORC∗1 haplotype (ethnic Africans) would probably
also beneﬁt from a more detailed genotyping program to
elucidate individual warfarin dosage requirements.
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